Serrapeptase does not kill viruses in the way an antiviral drug does. It is a proteolytic enzyme, meaning it breaks down proteins, and early lab studies suggest it can inactivate certain viruses in a test tube. But no human clinical trials have confirmed that taking serrapeptase orally stops or treats a viral infection. In the United States, it is classified as a dietary supplement, not an approved antiviral medication.
What Lab Studies Actually Show
The most direct evidence comes from a preliminary study that tested serrapeptase and several other enzyme preparations against SARS-CoV-2 in cell cultures. At a concentration of 500 micrograms per milliliter, serrapeptase reduced viral levels by about 84%. That sounds impressive, but context matters: at a lower concentration of 50 micrograms per milliliter, serrapeptase showed zero inactivation. The effect was entirely dose-dependent, and the effective dose was achieved in a lab dish, not inside a human body.
Other enzyme blends tested in the same study performed better at lower concentrations. One product achieved the same 84% reduction at less than half the dose serrapeptase required. The researchers described these results as worth exploring further for potential use as a surface-level biocide to reduce transmission risk, not as an oral treatment for people already infected.
This is a critical distinction. Inactivating a virus in a petri dish is a very different challenge from doing so inside a living person, where the enzyme has to survive digestion, enter the bloodstream in meaningful amounts, and reach infected tissues at high enough concentrations. Many substances that kill viruses in lab settings, from bleach to alcohol, are useless or harmful as internal treatments.
How Serrapeptase Works in the Body
Serrapeptase is a protein-digesting enzyme originally found in the gut of silkworms, where it dissolves the tough silk cocoon so the moth can emerge. When taken as a supplement, it primarily acts as an anti-inflammatory and mucolytic agent. It breaks down proteins involved in inflammation and thins mucus.
The enzyme reduces the viscosity of nasal mucus without changing its elasticity, based on a clinical study that measured mucus properties over four weeks. It also lowers levels of inflammatory signaling molecules by interacting with the same pathways targeted by conventional anti-inflammatory drugs. Specifically, it reduces capillary permeability triggered by histamine, bradykinin, and serotonin, and it helps the body clear abnormal protein buildup at inflamed sites.
Some researchers have proposed that because proteolytic enzymes can interfere with the protein machinery viruses use to enter and replicate inside host cells, serrapeptase could theoretically disrupt viral infection. A 2021 paper in Frontiers in Pharmacology described it as a “promising candidate” for further study in COVID-19 management, citing its combination of anti-inflammatory, mucolytic, and potential antiviral properties. But “promising candidate for study” is not the same as “proven to work.”
Why It Might Help With Viral Symptoms
Where serrapeptase may offer indirect benefit during a viral illness is in managing the body’s inflammatory response. Many of the worst symptoms of respiratory infections, including swelling, congestion, pain, and difficulty breathing, are driven by inflammation rather than the virus itself. Serrapeptase’s ability to thin mucus, reduce swelling, and modulate immune cell migration to inflamed tissue could, in theory, ease some of those symptoms.
Unlike standard anti-inflammatory drugs, serrapeptase does not block the production of specialized molecules the body uses to resolve inflammation on its own. This means it may reduce swelling without interfering with the natural healing process, though this advantage has been better studied in post-surgical recovery than in viral illness.
Safety Considerations
Serrapeptase is generally tolerated at typical supplement doses of 10 to 60 milligrams per day. It has no formally listed contraindications, but it does carry real risks in certain situations. Because it breaks down proteins involved in clotting, it can increase bleeding risk if you take blood thinners or antiplatelet medications.
Rare but serious side effects have been reported, including a type of lung inflammation called eosinophilic pneumonitis, a blistering skin condition, and hemorrhage in a patient with an underlying vascular disorder. One case report documented a patient with a dental abscess whose infection spread into deeper tissue layers after taking serrapeptase. The enzyme’s ability to break down tissue barriers, normally a benefit for reducing swelling, allowed the existing infection to penetrate further.
This case highlights an important point: an enzyme that degrades proteins does not distinguish between helpful and harmful targets. During an active infection with localized pus or abscess formation, serrapeptase could theoretically make things worse rather than better.
The Bottom Line on Antiviral Claims
Serrapeptase can inactivate viruses in a lab setting at high concentrations. It has not been shown to do the same inside the human body. No clinical trial has demonstrated that taking serrapeptase prevents viral infection, reduces viral load in infected patients, or shortens the course of illness. The enzyme’s real, documented strengths are in reducing inflammation, thinning mucus, and supporting recovery from swelling. Those properties might ease discomfort during a respiratory infection, but they are not the same as killing a virus. Anyone selling serrapeptase as an antiviral treatment is getting ahead of the science.